40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call...Read more
FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo WILMINGTON, Del. / Nov 07, 2025 / Business Wire / Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated...Read more
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients...Read more
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p<0.0001) If approved,...Read more
FDA sets updated PDUFA goal date of March 20, 2026 Company to hold conference today at 8:00 a.m. BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living...Read more
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first...Read more
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Globus Medical | 22.18 35.94 | $83.89 |
| Intuitive | 12.22 2.23 | $560.00 |
| Regeneron Pharmaceuticals | 10.66 1.65 | $657.53 |
| ICU Medical | 10.49 8.09 | $140.16 |
| Cigna | 8.20 3.20 | $264.58 |
| Spruce Biosciences | 7.71 6.46 | $127.00 |
| Thermo Fisher Scientific | 6.43 1.14 | $572.41 |
| Labcorp | 6.08 2.47 | $252.72 |
| Cidara Therapeutics | 5.75 5.83 | $104.39 |
| Cardinal Health | 5.68 2.87 | $203.67 |
| HCA Healthcare | 5.25 1.11 | $476.61 |
| Solventum | 5.24 7.91 | $71.52 |
| Molina Healthcare | 4.94 3.36 | $152.06 |
| Amgen | 4.61 1.46 | $320.20 |
| Progyny | 4.36 24.21 | $22.37 |
| Soleno Therapeutics | 4.16 9.55 | $47.70 |
| Fulgent Genetics | 4.05 18.15 | $26.36 |
| Insmed | 4.02 2.17 | $189.70 |
| Company | Volume | Last Trade |
|---|---|---|
| SCWorx | 112,175,039 | $0.30 |
| Pfizer | 111,910,197 | $24.44 |
| Recursion | 98,061,874 | $4.63 |
| Organogenesis | 79,065,290 | $5.60 |
| Intellia Therapeutics | 72,466,795 | $9.54 |
| Iovance Biotherapeutics | 64,973,008 | $2.30 |
| Eledon Pharmaceuticals | 61,722,553 | $2.03 |
| Clover Health | 57,556,186 | $2.69 |
| AbCellera Biologics | 32,163,086 | $3.96 |
| Femasys | 27,382,435 | $1.03 |
| Oscar Health | 24,488,463 | $17.72 |
| Quantum-Si | 24,016,724 | $1.58 |
| Geron | 23,631,929 | $1.07 |
| AirSculpt Technologies | 23,314,936 | $6.45 |
| Sangamo Therapeutics | 20,751,673 | $0.47 |
| Lexicon Pharmaceuticals | 19,710,026 | $1.25 |
| Novo Nordisk | 18,888,296 | $45.58 |
| Incannex Healthcare | 17,147,774 | $0.35 |
| Rani Therapeutics | 16,798,964 | $2.02 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
